Cancer patients to continue promising treatments in major extension trial

NCT ID NCT07620574

Not yet recruiting Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical benefit for people with cancers like kidney, liver, thyroid, and prostate cancer. Participants must have been deriving benefit in their prior study and have no access to the treatment locally.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide
What this could lead to
If successful, this study could allow patients with various cancers to continue benefiting from their treatment for a longer period, potentially improving long-term outcomes.
What could go wrong
This is an extension study, not a new treatment test, so it won't prove new cures. Side effects from long-term drug use remain possible, and only patients already benefiting are eligible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.